Myriad receives reimbursement for the BRACAnalysis Diagnostic System in Japan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Myriad Genetics has received reimbursement and launched the BRACAnalysis Diagnostic System in Japan to help physicians determine which people affected with breast and ovarian cancer have hereditary breast and ovarian cancer syndrome and qualify for additional diagnostic and medical management.

BRACAnalysis was approved by Japan’s Ministry of Health, Labour and Welfare in November 2019 for this indication.

Table of Contents

YOU MAY BE INTERESTED IN

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login